Dermata Therapeutics Inc (DRMA)

1.26 -0.10 (-7.35%) USD  |  NASDAQ  |  Jan 08, 16:00
1.29 +0.03 (+2.38%) After-Hours: 20:00
More

Dermata Therapeutics SG&A Expense (Quarterly): 0.8243M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for DRMA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
MetaVia Inc 1.742M
Cognition Therapeutics Inc 3.071M
ZyVersa Therapeutics Inc 1.834M
NovaBay Pharmaceuticals Inc 2.65M
Palatin Technologies Inc 2.021M